Join us on August 13, 2024, at 8:00 AM ET for our quarterly earnings conference call where we will discuss our Q2 2024 financial results and provide business updates.
Links to press release and registration are in the first comments.
A new study finds that patients who take a single psychedelic dose of psilocybin, 25mg, in conjunction with therapy report rapid and significant reduction in depression symptoms.
The FDA has cleared MindMed’s IND application for MM-120, our proprietary, pharmacologically optimized form of LSD. Our Phase 2b dose-optimization trial of MM-120 for the treatment of Generalized Anxiety Disorder is expected to start in early 2022.
"A 2020 study from Johns Hopkins University showed that two doses of psilocybin produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of the study participants achieving full remission."
Research has shown that psychedelics can help treat historically difficult-to-treat conditions by essentially “reshaping” the way “parts of the brain talk to each other.” Companies like MindMed are helping pave the way.
"'Magic Mushrooms' can cause an increase in the number of neuronal connections and thus position itself as one of the better treatments for major depression." Learn more:
MindMed is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD).
"Alcohol accounts for about 3 million deaths worldwide annually, and there are only four approved drugs to treat alcohol use disorder." Find out how German researchers are using psilocybin to cut alcohol cravings and boost key brain functions.
Today, we announced the FDA has granted breakthrough therapy designation for MM120 in GAD. We also announced positive 12-week durability data from our Phase 2b study of MM120 in GAD and are hosting a call at 8AM ET to discuss details. Read more: $MNMD
MindMed Leverages psychoactive brew ayahuasca which is known for having a fast-onset antidepressant effect. Learn more about how serotonergic psychedelics are giving promising results in the quest for alternative treatments for depression and anxiety here:
The entire
#mindmed
team is excited to welcome Robert Barrow as Chief Development Officer. Mr. Barrow was responsible for launching the Phase 2 clinical program for psilocybin in the treatment of Major Depressive Disorder and for obtaining BTD for the program at
@US_FDA
Everyone at
#mindmed
is extremely pleased to announce the close of our acquisition of
@healthmodeHQ
!
@healthmodeHQ
measurements will be used to improve efficiency & efficacy of clinical development and clinical care. More details here:
@thejrrahn
Researchers say “psychedelic-assisted psychotherapy” could be more effective at treating the symptoms of “PTSD, depression, anxiety, addictions, and social disconnection”.
We're proud to be the first
#psychedelic
company to go public last year. It's just the beginning,
@thejrrahn
said it best, "We are still in the early innings here".
@kevinolearytv
The American mental health system is being re-engineered around psychedelics, and clinical psychedelics could begin receiving FDA approval as early as 2023. Learn more about the future of mental health and how MindMed is spearheading the change here.
The U.S. Government recently awarded Johns Hopkins a grant to research how psychedelic therapy can impact tobacco addiction. Learn more about the grant here:
The Lancet Commission report on mental health said, "Mental disorders will cost the global economy $16 trillion by 2030"
Mental health is not getting better.
@mindmedco
is working diligently to explore new approaches to the growing mental health crisis.
#psychedelic
#biotech
May is Mental Health Awareness Month! Here at MindMed, we help showcase the potential benefits that psychedelic drugs can have on one's mental health. 🍄
"NYU Langone Health and the NYU Grossman School of Medicine are ideal partners for MindMed as we continue to evaluate and research future psychedelic assisted therapies and medicines for substance abuse disorders and other mental illnesses" -
@thejrrahn
@hanfrish
#psychedelics
UW-Madison School of Pharmacy professor Paul Hutson states that "Psychedelic research on campus has shown that MDMA in combination with psychotherapy can reduce symptoms of PTSD by as much as 300 percent in patients." Learn more about the program here:
The time has come...
#mindmed
is launching its
#merch
program with net proceeds going directly to your choice of non-profit organization. These will initially include
@MAPS
and
@nyulangone
Psychedelic Research Program!
The latest swag can be found here:
It’s time to destigmatize mental illness and psychedelics. 🧠
@DeepakChopra
chatted with
@chelseahandler
about MindMed and the potential benefits that psychedelic drugs can have.
The first time I took acid would have been at The Limelight in NYC around the age of 17. What was your first psychedelic experience?
Listen to my talk with
@DeepakChopra
and more on the latest episode of Dear Chelsea.
MindMed today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of LSD. Learn more about the trial here:
If you haven't had a chance to checkout MindMed's revamped website, head over to !
The most up to date news on clinical trials and all other
@mindmedco
initiatives within
#psychedelics
can be found here.
#biotech
The
@US_FDA
is participating in the
#DigitalHealth
collaborative community, an effort to develop best practices and streamline the field’s approaches to measuring health using digital technologies. Find out more:
MindMed welcomes our new CEO
@RobertBBarrow
. After serving as interim CEO and CDO of MindMed, we are excited to have Rob bring his strategic expertise and deep industry insight to this role.
MindMed is excited to announce that it has joined the Critical Path Institute's ("C-Path's") Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science. Learn more here:
“I believe Psychedelics are going to be a multi-billion dollar pharmacy space.” Kevin O’Leary joins Midas Letter and talks about the future of MindMed. Check out their interview here ⬇️
We have officially received a positive response on protocol design for a Phase 2a clinical trial evaluating microdoses of LSD in the treatment of adult ADHD from the Swiss and Dutch health authorities.
Pandemic stress has left the mental health of frontline health care workers in a state of crisis. The University of Washington will treat 30 medical professionals diagnosed with depression with a dose of synthetic psilocybin along with psychotherapy.
Despite the fact that around 450 million people globally suffer from mental illnesses, access to mental healthcare is still a challenge and it's crucial to provide treatment. MindMed is helping by using psychedelic medicines and therapies. Learn more:
Today we celebrated (almost) one year as a Nasdaq-listed company. Thank you to
@Nasdaq
for hosting us and thank you to all of our teammates, both near and far, who made this day possible. There's so much more to come!
Investors are looking into new potential therapies like
#psychedelics
to transform how we treat mental health.
Checkout
@Forbes
reporting on the subject here:
"Why Investors Are Bullish On Psychedelics"
While there’s no doubt that ketamine reduces depression by inhibiting the NMDA receptor. Some scientists including neuropharmacologist, Todd Gould, think there’s more to the story. Find the full article below.
There’s a vast body of research that points to the therapeutic benefits psychedelic treatment can provide for people with mental health issues. We are committed to studying these options in a safe, rigorous, and federally-compliant way.
Excited to be partnering with Datavant! We will be utilizing Datavant's linking technology across various stages of the drug lifecycle including discovery, clinical development, and commercialization. Learn more here:
As psychedelic therapy is becoming more mainstream - it's important to know just how "magic mushrooms" can potentially be used to treat mental health diagnoses, such as depression and post-traumatic stress disorder (PTSD).
Psychedelics are changing society's approach to mental health. To better understand how psychedelics will transform psychiatry, read more through the link below.
Through its recent collaboration with Forian, MindMed has a first to market opportunity to develop an individualized, personalized treatment for anxiety-related disorders. Read more here:
“We’re not OK,”
@JamonRahn
told
@nathanheller
. 11% of Americans seriously considered suicide in June. It’s time for innovative and novel solutions to society’s mental health crises. MindMed’s work with
@NYULangone
aims to create them. More in
@NewYorker
:
Our co-founder and CEO
@JamonRahn
spoke at the
@Benzinga
Small Cap Conference about the story behind MindMed, the impact of COVID-19 on our mental health, and how we achieved unicorn status for the first time earlier this week. Watch here:
.
@kevinolearytv
likes to invest in “novel solutions to big problems.” Addressing our society’s mental health and substance abuse crises might be the biggest problem yet. It’s an honor to have him on this mission with us.
"At least 8.9 million American adults have both mental illness and substance use disorder. Yet millions go untreated because of the structural separation between mental health and addiction services."
#WorldMentalHealthDay
The psychedelic industry is constantly growing and now including the development of psychedelic-inspired therapies to address addiction and mental illnesses. Learn more:
As the COVID-19 pandemic raged, so did the country’s other epidemic. Drug overdose deaths rose nearly 30 percent in 2020 to a record 93,000. MindMed is hard at work to battle this ongoing epidemic. Learn more:
Our Phase 2b trial of MM120 in GAD patients met its key secondary endpoint, demonstrating clinically & statistically significant durability of activity observed through week 12 after a single dose with no additional therapeutic intervention. Read more:
As Warren Buffet once said, “only when the tide goes out do you discover who's been swimming naked." MindMed, however, is serious about becoming a long-term leader in the biotech sector.
With the rise in opioid-related deaths, prescribers are put in a difficult position when treating patients struggling with mental health. Psychedelics can be a safe and effective new solution.
Promising studies and destigmatization are making psychedelics an increasingly viable treatment for mental illness. Learn more about the history and future of psychedelic therapy here:
“How we’re going to differentiate is to continue to take a rigorous scientific and pharmaceutical development approach… bringing in top people [and] novel assets,”
@mindmedco
's Robert Barrow says. “We’re not selling psilocybin. Our early assets are LSD and an ibogaine analogue.”
"Social anxiety disorder is a prevalent and often debilitating psychiatric disorder that can assume a chronic course even when treated." Learn more about MDMA-assisted therapy here:
Tune in to
@MadMoneyOnCNBC
this evening at 6pm ET, where our CEO, Robert Barrow, sits down with host,
@JimCramer
to discuss the business of MindMed. $MNMD
@CNBC
Our next "Mind behind MindMed" is Chief Medical Officer Daniel R. Karlin, MD MA. He led clinical, informatics, and regulatory strategy and served as Global Clinical Lead for psychiatry clinical compounds for Pfizer. He now leads MindMed's work in digital medicine.
Today, we launched Albert, a new digital medicine division aimed at developing a more robust understanding of the value of a treatment and long-term impact on patient outcomes.
We can't wait for Dr. Liechti to share his latest work, which we believe validates MindMed's clinical approach to developing LSD for anxiety disorders. This data builds on a scientific legacy dating back to the 1940s!
The
#addiction
pandemic has been exacerbated by Covid-19. Creating a new paradigm of
#addiction
treatments is
@mindmedco
's mission. "Deaths attributed to synthetic opioids, mainly fentanyl, increased 38 percent nationwide, but 98 percent in 10 western states." More below: